200000456-4
IP03

PCT WORLD INTELLECTUAL PROPERTY ORGANIZATION
International Bureau

INTERNATIONAL APPLICATION PUBLISHED UNDER THE PATENT COOPERATION TREATY (PCT)

(51) International Patent Classification 6 : A61K 9/12

A1

(11) International Publication Number: WO 99/06025

(43) International Publication Date: 11 February 1999 (11.02.99)

(21) International Application Number: PCT/US98/16111

(22) International Filing Date: 4 August 1998 (04.08.98)

(30) Priority Data:
08/904,565 4 August 1997 (04.08.97) US

(71) Applicant: BAKER NORTON PHARMACEUTICALS, INC. [US/US]; 4400 Biscayne Boulevard, Miami, FL 33137 (US).

(72) Inventor: AHMED, Tahir; 1020 South Greenway Drive, Coral Gables, FL 33134 (US).

(74) Agent: SCHIFFMILLER, Martin, W.; Kirschstein, Ottinger, Israel & Schiffmiller, P.C., 489 Fifth Avenue, New York, NY 10017–6105 (US).

(81) Designated States: AL, AM, AT, AU, AZ, BA, BB, BG, BR, BY, CA, CH, CN, CU, CZ, DE, DK, EE, ES, FI, GB, GE, GH, GM, HR, HU, ID, IL, IS, JP, KE, KG, KP, KR, KZ, LC, LK, LR, LS, LT, LU, LV, MD, MG, MK, MN, MW, MX, NO, NZ, PL, PT, RO, RU, SD, SE, SG, SI, SK, SL, TJ, TM, TR, TT, UA, UG, UZ, VN, YU, ZW, ARIPO patent (GH, GM, KE, LS, MW, SD, SZ, UG, ZW), Eurasian patent (AM, AZ, BY, KG, KZ, MD, RU, TJ, TM), European patent (AT, BE, CH, CY, DE, DK, ES, FI, FR, GB, GR, IE, IT, LU, MC, NL, PT, SE), OAPI patent (BF, BJ, CF, CG, CI, CM, GA, GN, GW, ML, MR, NE, SN, TD, TG).

Published
With international search report.

(54) Title: METHOD AND COMPOSITIONS FOR TREATING LATE PHASE ALLERGIC REACTIONS AND INFLAMMATORY DISEASES

(57) Abstract

A method of treating a mammalian patient suffering from or prone to a condition characterized by late phase allergic reactions, airway hyperresponsiveness or inflammatory reactions, e.g., asthma, allergic rhinitis, allergic dermatitis, allergic conjunctivitis, inflammatory bowel disease or rheumatoid arthritis, comprising the administration to the patient of an oral, parenteral, intrabronchial, topical, intranasal or intraocular pharmaceutical composition containing in each dose about 0.005 to about 1.0 mg per kilogram of patient body weight of ultra–low molecular weight heparins (ULMWH) or other sulfated polysaccharides having average molecular weights of about 1,000–3,000 daltons. Suitable inhalant and other pharmaceutical compositions for use in the novel treatment method are also disclosed.